Matts serves as Kronos Bio’s vice president of U.S./Global Market Access and Reimbursement, with responsibility for building and advancing the organization’s patient access capabilities in preparation for the potential launch of the company’s first therapies. Matt joined Kronos Bio in 2022 from Oncopeptides, where in his most recent role he was vice president and head of Market Access, Distribution and Supply Chain. In that role, Matt was responsible for leading the build out of the U.S.-based market access team to support the launch of the company’s multiple myeloma medicine. Prior to Oncopeptides, Matt served as executive director of Market Access at Dynavax Technologies, where he was responsible for trade and distribution, pricing, heath economics and payer engagement. Earlier in his career, Matt worked in a number of market access, market analysis and strategy roles at XOMA, Medivation and Genentech.

Matt holds an MBA from the University of San Francisco and a BA from Connecticut College in Behavioral Psychology and Pre-Medical Sciences.